Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction more efficiently while increasing the anatomic accuracy and likely durability of the repair.
In this first such case, the combined technology allowed a more precise fit for an implant crafted from the patient’s fibula.
“When there is a really good fit, the survivorship of the...
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the roughly 15,000 patients diagnosed annually, only 5-10% will survive five years.
The Glioblastoma Moon Shot® is working to change those odds and save the lives of patients with a coordinated, multidisciplinary team of researchers and physicians committed to findings new vulnerabilities, testing...
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival...
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including surgery...
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...